ABSTRACT
Adenine phosphoribosyltransferase (APRT) is the key enzyme involved in purine salvage by the incorporation of adenine and phosphoribosyl pyrophosphate to provide adenylate nucleotides. To evaluate the role of APRT in the repair processes of cutaneous wounds in healthy skin and in diabetic patients, a diabetic mouse model (db/db) and age-matched wild-type mice were used. Moreover, the topical application of adenine was assessed. In vitro studies, analytical, histological, and immunohistochemical methods were used. Diabetic mice treated with adenine exhibited elevated ATP levels in organismic skin and accelerated wound healing. In vitro studies showed that APRT utilized adenine to rescue cellular ATP levels and proliferation from hydrogen peroxide-induced oxidative damage. HPLC-ESI-MS/MS-based analysis of total adenylate nucleotides in NIH-3T3 fibroblasts demonstrated that adenine addition enlarged the cellular adenylate pool, reduced the adenylate energy charge, and provided additional AMP for the further generation of ATP. These data indicate an upregulation of APRT in skin wounds, highlighting its role during the healing of diabetic wounds through regulation of the nucleotide pool after injury. Furthermore, topical adenine supplementation resulted in an enlargement of the adenylate pool needed for the generation of ATP, an important molecule for wound repair.
Subject(s)
Adenine Phosphoribosyltransferase/physiology , Diabetes Mellitus, Experimental/physiopathology , Wound Healing/physiology , Adenine/pharmacology , Adenosine Triphosphate/metabolism , Animals , Cell Movement/drug effects , Cells, Cultured , Energy Metabolism/drug effects , Humans , Male , Mice , Mice, Inbred C57BL , NIH 3T3 Cells , Wound Healing/drug effectsABSTRACT
Constraint-based modeling for genome-scale metabolic networks has emerged in the last years as a promising approach to elucidate drug targets in cancer. Beyond the canonical biosynthetic routes to produce biomass, it is of key importance to focus on metabolic routes that sustain the proliferative capacity through the regulation of other biological means in order to improve in-silico gene essentiality analyses. Polyamines are polycations with central roles in cancer cell proliferation, through the regulation of transcription and translation among other things, but are typically neglected in in silico cancer metabolic models. In this study, we analysed essential genes for the biosynthesis of polyamines. Our analysis corroborates the importance of previously known regulators of the pathway, such as Adenosylmethionine Decarboxylase 1 (AMD1) and uncovers novel enzymes predicted to be relevant for polyamine homeostasis. We focused on Adenine Phosphoribosyltransferase (APRT) and demonstrated the detrimental consequence of APRT gene silencing on different leukaemia cell lines. Our results highlight the importance of revisiting the metabolic models used for in-silico gene essentiality analyses in order to maximize the potential for drug target identification in cancer.
Subject(s)
Adenine Phosphoribosyltransferase/metabolism , Adenine Phosphoribosyltransferase/physiology , Polyamines/metabolism , Adenosylmethionine Decarboxylase/metabolism , Biochemical Phenomena , Cell Line, Tumor , Cell Proliferation , Computer Simulation , Genes, Essential/genetics , Homeostasis , Humans , Leukemia/genetics , Metabolic Networks and Pathways , Neoplasms/genetics , PolyelectrolytesABSTRACT
Adenine phosphoribosyltransferase (APRT) deficiency is a genetic disorder that causes 2,8-dihydroxyadenine (DHA) urolithiasis. Based on the level of residual enzyme activity in cell extracts, two types of APRT deficiency have been identified. Type I is complete enzyme deficiency. Type II shows residual activity in cell lysates, but enzyme activity is not demonstrable in intact cells. Patients with type II have at least one M136T allele and have been identified mainly in Japanese. Thus, in Japanese, patients with type I deficiency are homozygous for APRT*Q0 (null alleles) and patients with type II deficiency are either homozygotes with APRT*J (M136T allele) or compound heterozygotes with APRT*J/APRT*Q0.
Subject(s)
Adenine Phosphoribosyltransferase/deficiency , Purines/metabolism , Adenine/analogs & derivatives , Adenine Phosphoribosyltransferase/genetics , Adenine Phosphoribosyltransferase/physiology , Alleles , Asian People , Genotype , Humans , Mutation , Urolithiasis/etiologyABSTRACT
A cardiomiopatia hipertrófica é doença genética autossômica dominante em mais da metade dos casos. Foram descritas, até o momento, mais de 270 mutações em dez genes que codificam proteínas do sarcômero cardíaco. Para cada gene existem diversas mutações, cada qual com particularidades quanto a hipertrofia miocárdica, penetrância e prognóstico, principalmente em relação a morte súbita. Há evidência de que outro fatores genéticos têm papel na hipertrofia da cardiomiopatia hpertrófica, como o polimorfismo no gene da enzima conversora da angiotensina e em outros genes modificadores, ambos podendo influenciar o grau de hipertrofia e, eventualmente, a ocorrência de morte súbita. Neste artigo são descritas as mutações relatadas na literatura, assim como nossa experiência no Instituto do Coração, que é a primeira no Brasil nessa moléstia
